Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder.
about
The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorderA systematic review of reboxetine for treating patients with attention deficit hyperactivity disorderDo adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorderEfficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.Drug therapy of attention deficit hyperactivity disorder: current trends.Innovations and recent trends in the treatment of ADHD.Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System.Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention deficit-hyperactivity disorder with comorbid anxiety disorders.Reboxetine in therapy-resistant enuresis: a retrospective evaluation.The effects of reboxetine treatment on depression-like behavior, brain neurotrophins, and ERK expression in rats exposed to chronic mild stress.
P2860
Q22241830-64A3EF13-A54E-4836-BAA7-915ECA77E24BQ28251940-5898500F-422A-4B12-ABB9-12C66A043BCFQ28274915-AE3E3EDA-D12C-4B34-9DE6-5A642C6348FDQ34041736-9F907099-D8DE-44AF-B10A-74FE4A01A273Q34163924-98C1B64C-4965-471E-9B84-6FB65653F011Q35964370-1C1899E4-FF87-4056-B2A6-63FB8A8AEB0AQ36607357-75C5C9F3-7B27-4DC2-8C0A-4F0C01EE148FQ37158450-92BE718D-5F65-4432-BC81-BACAE441124EQ38583272-997F9936-41C4-4063-8D96-94A773CCFE58Q41515634-90D88392-1311-4D1B-B737-0DAE896932BDQ43239651-2907221C-E4A5-4CE8-96F0-43061CCDC9B8Q43676192-3B69AF09-53B7-47CB-9477-E14D130A6E51
P2860
Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@ast
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@en
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@nl
type
label
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@ast
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@en
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@nl
prefLabel
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@ast
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@en
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@nl
P2093
P921
P1476
Six-week open-label reboxetine ...... eficit/hyperactivity disorder.
@en
P2093
Abraham Weizman
Nathaniel Laor
Sharon Ratner
Yifat Bronstein
P304
P356
10.1097/01.CHI.0000155327.30017.8C
P577
2005-05-01T00:00:00Z